I really think you guys need to read between the lines. The results announcement to the ASX is a masterclass in polishing a turd.... Although, It could not be any clearer that the primary endpoint of the Trial was NOT MET.
How on earth can you refute the below???
ASX Announcement of Trial overview
Study Overview
The randomised, double-blinded, placebo-controlled clinical study of VIRALEZE™ assesses SARS-CoV-2 viral load in the nasal cavity of patients with COVID-19 while using VIRALEZE™. The primary endpoint of the clinical study is the level of a patient’s viral load over a seven-day treatment period.
ASX Announcement of trial results:
Viraleze™ reduced viral load in the full study population including all patient age groups (N=197), although the difference vs placebo was not statistically significant.
SPL Price at posting:
9.7¢ Sentiment: Hold Disclosure: Held
